Survodutide
Intervention4 papers2 findingsPubChem 171378821
- Human trial2
Outcomes
2Gastrointestinal adverse events
upin humans1
1 study
Gastrointestinal adverse events
upin humans1
Survodutide increases gastrointestinal adverse events in humans.
Review
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties · Contemporary clinical trials · 1 Oct 2026
Body weight
downin humans1
1 study
Body weight
downin humans1
Survodutide decreases body weight in humans (18.7% vs 2.3% with placebo).
Review4.8-mg46 weeks
Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties · Contemporary clinical trials · 1 Oct 2026
Latest
4Survodutide reduces weight in adults with diabetes and obesity
Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.Weekly survodutide cut body weight by up to 9.8% at 76 weeks compared to a 3.9% reduction with placebo.